US69366J2006 - Common Stock
PTC THERAPEUTICS INC
NASDAQ:PTCT (5/15/2024, 4:20:01 PM)
After market: 33.66 0 (0%)33.66
+2.48 (+7.95%)
PTC Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in South Plainfield, New Jersey and currently employs 1,402 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The company also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).
PTC THERAPEUTICS INC
100 Corporate Ct
South Plainfield NEW JERSEY 07080
P: 19082227000
CEO: Stuart W. Peltz
Employees: 1402
Website: https://www.ptcbio.com/
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: RBC...
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.
PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips PTC Therapeutics (NASDAQ:PTCT) just reported results for the first quarter of 2...
/PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024....
Here you can normally see the latest stock twits on PTCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: